# NanO2 for Large Vessel Occlusion Stroke

Study · id `cardio:ct-nct05389748` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05389748](<https://clinicaltrials.gov/study/NCT05389748>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05389748

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05389748. Randomized; single masking; primary purpose treatment. Start 2023-04-01 (anticipated); primary completion 2025-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05389748, source copy `cardio:ctgov-nct05389748-2022-05-25`, retrieved 2026-10-26)
- Planned start: 2023-04-01 (anticipated) (ClinicalTrials.gov record NCT05389748, source copy `cardio:ctgov-nct05389748-2022-05-25`, retrieved 2026-10-26)
- Primary completion: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT05389748, source copy `cardio:ctgov-nct05389748-2022-05-25`, retrieved 2026-10-26)
- Completion: 2025-09-01 (anticipated) (ClinicalTrials.gov record NCT05389748, source copy `cardio:ctgov-nct05389748-2022-05-25`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05389748-2022-05-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: NanO2 for Large Vessel Occlusion Stroke
- Acronym: PROVEN
- Condition: Ischemic Stroke
- Intervention (Other): Placebo
- Intervention (Biological): dodecafluoropentane emulsion (DDFPe)
- Lead sponsor: NuvOx LLC
- Lead sponsor class: INDUSTRY
- Collaborator: University of Arkansas
- Collaborator class: OTHER
- Collaborator: Stanford University
- Collaborator class: OTHER
- Collaborator: Washington Regional Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: University of Arkansas (`cardio:org-university-of-arkansas`)
- Registry lists this organization as a collaborator: Stanford University (`cardio:org-stanford-university`)

## Provenance

Content hash: 268e33d309929a4b9afc87f3ceaba708760c3d186d71608b94a194576b975948
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
